Angiogenesis patch trial moves forward:
This article was originally published in Clinica
Advanced Tissue Sciences has begun a pivotal preclinical trial of its tissue-engineered epicardial patch for stimulating new blood vessel growth and improving the function of damaged heart tissue. The trial will assess the safety of the patch, called Anginera, in large animals. A previous study in mice has shown that the patch can improve overall function in damaged heart tissue without adversely effecting normal heart tissue function. Studies in large animals are required by the US FDA before starting human trials, noted the La Jolla, California firm. An efficacy trial in large animals is to begin this summer.
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.